investigating prognostic markers for os with lupsma treatment in mcrpc
Published 4 years ago • 49 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
4:56
improving the prognosis for patients with mcrpc
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
11:39
psmafore trial & enzalutamide with 177lu-psma-617 for mcrpc | dr. dharmender malik | 05th knowledge
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
3:30
radionuclide conjugates 225ac-j591 and 177lu-psma-i&t for mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
7:44
vision trial supports lupsma-targeting therapy for mcrpc | michael morris
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
7:52
case 3: treatment after progression to mcrpc
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
0:53
os and biomarker results from combat: bipolar androgen therapy plus nivo for patients with mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
4:48
vision: lu-177-psma-617 in mcrpc